These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 35053170)
21. MDM2 mediates fibroblast activation and renal tubulointerstitial fibrosis via a p53-independent pathway. Ye C; Tang H; Zhao Z; Lei CT; You CQ; Zhang J; Gao P; He FF; Chen S; Wang YM; Zhang C; Su H Am J Physiol Renal Physiol; 2017 Apr; 312(4):F760-F768. PubMed ID: 28100501 [TBL] [Abstract][Full Text] [Related]
22. HAUSP-nucleolin interaction is regulated by p53-Mdm2 complex in response to DNA damage response. Lim KH; Park JJ; Gu BH; Kim JO; Park SG; Baek KH Sci Rep; 2015 Aug; 5():12793. PubMed ID: 26238070 [TBL] [Abstract][Full Text] [Related]
23. A site-directed mutagenesis study of the MdmX RING domain. Egorova O; Mis M; Sheng Y Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078 [TBL] [Abstract][Full Text] [Related]
24. Insulin receptor tyrosine kinase substrate enhances low levels of MDM2-mediated p53 ubiquitination. Wang KS; Chen G; Shen HL; Li TT; Chen F; Wang QW; Wang ZQ; Han ZG; Zhang X PLoS One; 2011; 6(8):e23571. PubMed ID: 21887275 [TBL] [Abstract][Full Text] [Related]
25. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084 [TBL] [Abstract][Full Text] [Related]
26. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3. Yang P; Chen W; Li X; Eilers G; He Q; Liu L; Wu Y; Wu Y; Yu W; Fletcher JA; Ou WB Oncotarget; 2016 May; 7(22):32652-63. PubMed ID: 27129163 [TBL] [Abstract][Full Text] [Related]
27. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100 [TBL] [Abstract][Full Text] [Related]
28. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236 [TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Palani CD; Beck JF; Sonnemann J Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659 [TBL] [Abstract][Full Text] [Related]
30. Mdm2 facilitates the association of p53 with the proteasome. Kulikov R; Letienne J; Kaur M; Grossman SR; Arts J; Blattner C Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10038-43. PubMed ID: 20479273 [TBL] [Abstract][Full Text] [Related]
31. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Gopal YN; Chanchorn E; Van Dyke MW Mol Cancer Ther; 2009 Mar; 8(3):552-62. PubMed ID: 19276167 [TBL] [Abstract][Full Text] [Related]
32. Hantaan virus nucleocapsid protein stimulates MDM2-dependent p53 degradation. Park SW; Han MG; Park C; Ju YR; Ahn BY; Ryou J J Gen Virol; 2013 Nov; 94(Pt 11):2424-2428. PubMed ID: 23994832 [TBL] [Abstract][Full Text] [Related]
33. Abnormal MDMX degradation in tumor cells due to ARF deficiency. Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712 [TBL] [Abstract][Full Text] [Related]
34. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. Sasaki M; Nie L; Maki CG J Biol Chem; 2007 May; 282(19):14626-34. PubMed ID: 17363365 [TBL] [Abstract][Full Text] [Related]
35. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function. Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313 [TBL] [Abstract][Full Text] [Related]
36. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571 [TBL] [Abstract][Full Text] [Related]
37. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function. Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907 [TBL] [Abstract][Full Text] [Related]
38. Dynamics in the p53-Mdm2 ubiquitination pathway. Brooks CL; Gu W Cell Cycle; 2004 Jul; 3(7):895-9. PubMed ID: 15254415 [TBL] [Abstract][Full Text] [Related]
39. Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IκB. Son DS; Kabir SM; Dong YL; Lee E; Adunyah SE PLoS One; 2012; 7(12):e51116. PubMed ID: 23300534 [TBL] [Abstract][Full Text] [Related]
40. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]